Head to Head Analysis: Jaguar Animal Health (NASDAQ:JAGX) vs. Tilray Brands (NASDAQ:TLRY)

Jaguar Animal Health (NASDAQ:JAGX) and Tilray Brands (NASDAQ:TLRY) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, analyst recommendations, dividends and profitability.

Valuation and Earnings

This table compares Jaguar Animal Health and Tilray Brands”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jaguar Animal Health	$27.79 million	0.11	-$53.43 million	($3,731.33)	-0.00
Tilray Brands	$915.45 million	0.41	-$121.40 million	($1.40)	-1.81

Jaguar Animal Health has higher earnings, but lower revenue than Tilray Brands. Tilray Brands is trading at a lower price-to-earnings ratio than Jaguar Animal Health, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Jaguar Animal Health has a beta of -0.11, suggesting that its share price is 111% less volatile than the S&P 500. Comparatively, Tilray Brands has a beta of 1.91, suggesting that its share price is 91% more volatile than the S&P 500.

Insider and Institutional Ownership

12.0% of Jaguar Animal Health shares are owned by institutional investors. Comparatively, 9.3% of Tilray Brands shares are owned by institutional investors. 0.1% of Jaguar Animal Health shares are owned by insiders. Comparatively, 1.6% of Tilray Brands shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Jaguar Animal Health and Tilray Brands’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Jaguar Animal Health	-187.88%	N/A	-131.45%
Tilray Brands	-16.91%	-10.39%	-7.38%

Analyst Recommendations

This is a summary of current ratings and recommmendations for Jaguar Animal Health and Tilray Brands, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jaguar Animal Health	1	0	0	0	1.00
Tilray Brands	2	2	3	1	2.38

Tilray Brands has a consensus target price of $5.90, indicating a potential upside of 133.20%. Given Tilray Brands’ stronger consensus rating and higher possible upside, analysts clearly believe Tilray Brands is more favorable than Jaguar Animal Health.

Summary

Tilray Brands beats Jaguar Animal Health on 11 of the 15 factors compared between the two stocks.

About Jaguar Animal Health

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.

About Tilray Brands

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada.